{"classes":[{"categories":[{"measurements":[{"comment":"NA - The follow-up was too short that the quantiles of the survival distribution could not be estimated.","groupId":"OG000","lowerLimit":"11.1","upperLimit":"NA","value":"NA"},{"comment":"NA - The follow-up was too short that the quantiles of the survival distribution could not be estimated.","groupId":"OG001","lowerLimit":"11.0","upperLimit":"NA","value":"15.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Time to progression (TTP) was defined as the time from the date of randomization to the date of the first documented PD per investigator's assessment or death due to study indication.\n\nTime to progression was analyzed by the Kaplan Meier method. Based on the Guidelines for Implementation of international working group (IWG) response criteria in AML, MDS and CMML according to Cheson 2003 and 2006.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.\n\nIn both phases, dose of 5-Azacytidine was 75 mg/m\\^2, subcutaneously Daily for Day 1 to Day 7.","id":"OG000","title":"Panobinostat + 5-Azacytidine"},{"description":"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.\n\nDose of 5-Azacytidine : 75 mg/m\\^2 subcutaneously daily from Day 1 to Day 7.","id":"OG001","title":"5-Azacytidine"}],"paramType":"MEDIAN","populationDescription":"Full analysis set: Consisted of all patients who were randomized to one of the two treatment arms","reportingStatus":"POSTED","timeFrame":"48 months","title":"Time to Progression (TTP) (Phase Llb)","type":"SECONDARY","unitOfMeasure":"months"}